Evolving Concepts in Progressive Pulmonary Fibrosis: A Clinical Update
Authors:
- María Belén Noboa-SevillaMNMaría Belén Noboa-Sevilla
- Fernanda Hernández-GonzálezFernanda Hernández-González
- Sandra Cuerpo-CardeñosaSCSandra Cuerpo-Cardeñosa
- Xavier Alsina-RestoyXAXavier Alsina-Restoy
- Nancy Pérez-RodasNPNancy Pérez-Rodas
- Alejandro Frino-GarcíaAFAlejandro Frino-García
- Miguel Alonso-VillaresMAMiguel Alonso-Villares
- Elvis Matheus-RamírezEMElvis Matheus-Ramírez
- Jacobo SellarésJacobo Sellarés
Open Access
- 1 September 2025
- journal article
- research article
- Published by MDPI AG in Journal of Respiration
- Vol. 5 (3) , 14
Abstract
Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.Keywords
This publication has 16 references indexed in Scilit:
- Current State of Fibrotic Interstitial Lung Disease ImagingRadiology, 2025
- Interstitial Lung DiseaseJAMA, 2024
- Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosisScientific Reports, 2024
- Functional Criteria to Define Progressive Pulmonary Fibrosis: Searching for the Holy GrailAmerican Journal of Respiratory and Critical Care Medicine, 2023
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2022
- Spectrum of Fibrotic Lung DiseasesNew England Journal of Medicine, 2020
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2013
- Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisThorax, 2012